231 related articles for article (PubMed ID: 3189311)
1. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group.
Cheson BD; Bennett JM; Rai KR; Grever MR; Kay NE; Schiffer CA; Oken MM; Keating MJ; Boldt DH; Kempin SJ
Am J Hematol; 1988 Nov; 29(3):152-63. PubMed ID: 3189311
[TBL] [Abstract][Full Text] [Related]
2. Study design in chronic lymphocytic leukemia.
Cheson BD
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):407-10. PubMed ID: 3065736
[TBL] [Abstract][Full Text] [Related]
3. Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL).
Eichhorst B; Hallek M
Best Pract Res Clin Haematol; 2007 Sep; 20(3):469-77. PubMed ID: 17707834
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
Hallek M; Cheson BD; Catovsky D; Caligaris-Cappio F; Dighiero G; Döhner H; Hillmen P; Keating MJ; Montserrat E; Rai KR; Kipps TJ;
Blood; 2008 Jun; 111(12):5446-56. PubMed ID: 18216293
[TBL] [Abstract][Full Text] [Related]
5. Current approaches to the chemotherapy of B-cell chronic lymphocytic leukemia: a review.
Cheson BD
Am J Hematol; 1989 Sep; 32(1):72-7. PubMed ID: 2667343
[TBL] [Abstract][Full Text] [Related]
6. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
Cheson BD; Bennett JM; Grever M; Kay N; Keating MJ; O'Brien S; Rai KR
Blood; 1996 Jun; 87(12):4990-7. PubMed ID: 8652811
[No Abstract] [Full Text] [Related]
7. Current status and future directions of clinical trials in chronic lymphocytic leukemia.
Nerenstone SR; Archer JI; Cheson BD
Oncology (Williston Park); 1987 Oct; 1(8):31-40, 44. PubMed ID: 3079490
[TBL] [Abstract][Full Text] [Related]
8. New modalities of therapy in chronic lymphocytic leukemia.
Cheson BD
Crit Rev Oncol Hematol; 1991 Sep; 11(3):167-77. PubMed ID: 1958310
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
[TBL] [Abstract][Full Text] [Related]
10. Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia.
Norin S; Kimby E; Lundin J
Med Oncol; 2010 Sep; 27(3):820-5. PubMed ID: 19705305
[TBL] [Abstract][Full Text] [Related]
11. Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.
Blum KA; Young D; Broering S; Lucas MS; Fischer B; Lin TS; Grever MR; Byrd JC
J Clin Oncol; 2007 Dec; 25(35):5624-9. PubMed ID: 17984187
[TBL] [Abstract][Full Text] [Related]
12. Early intervention in asymptomatic chronic lymphocytic leukemia.
Muchtar E; Kay NE; Parikh SA
Clin Adv Hematol Oncol; 2021 Feb; 19(2):92-103. PubMed ID: 33596191
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the treatment of B-cell chronic lymphocytic leukemia.
Cheson BD
Oncology (Williston Park); 1990 Sep; 4(9):71-8, 83-4; disc. 84, 87-8, 90 pass. PubMed ID: 2145022
[TBL] [Abstract][Full Text] [Related]
14. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
[TBL] [Abstract][Full Text] [Related]
15. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.
Sorensen JM; Vena DA; Fallavollita A; Chun HG; Cheson BD
J Clin Oncol; 1997 Feb; 15(2):458-65. PubMed ID: 9053466
[TBL] [Abstract][Full Text] [Related]
16. Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines.
Molica S; Giannarelli D; Mirabelli R; Levato L; Gentile M; Lentini M; Morabito F
Expert Rev Hematol; 2014 Oct; 7(5):691-5. PubMed ID: 25174547
[TBL] [Abstract][Full Text] [Related]
17. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
18. A review of pharmacologic options for previously untreated chronic lymphocytic leukemia.
Wilhelm K; Yang D
J Oncol Pharm Pract; 2011 Jun; 17(2):91-103. PubMed ID: 20085962
[TBL] [Abstract][Full Text] [Related]
19. Chronic lymphocytic leukemia: a clinical review.
Nabhan C; Rosen ST
JAMA; 2014 Dec; 312(21):2265-76. PubMed ID: 25461996
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia.
Binet JL; Caligaris-Cappio F; Catovsky D; Cheson B; Davis T; Dighiero G; Döhner H; Hallek M; Hillmen P; Keating M; Montserrat E; Kipps TJ; Rai K;
Blood; 2006 Feb; 107(3):859-61. PubMed ID: 16223776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
